Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Joseph Kubiak Jr

Pulmonary Disease Greenville, SC Medical Doctor

NPI 1639270598 CMS profile 28269

3 Saint Francis Dr, Suite 300, Greenville, SC 29601

Open in the dashboard

General payments

$4,622

268 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Joseph Kubiak Jr of Greenville, SC is reported in the CMS Open Payments database as having received $4,622 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $34 2
2023 General $47 3
2022 General $1,877 89
2021 General $889 53
2020 General $500 32
2019 General $1,276 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Kubiak Jr
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Joseph Kubiak Jr were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Joseph Kubiak Jr Pulmonary Disease median Middle half National median
2019 $1,276 $377 $109–$1,340 $163
2020 $500 $230 $56–$907 $114
2021 $889 $269 $68–$1,072 $132
2022 $1,877 $390 $100–$1,457 $149
2023 $47 $419 $114–$1,659 $160
2024 $34 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $496 39 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $412 25 payments
  3. Electromed, Inc. $395 29 payments
  4. Jazz Pharmaceuticals Inc. $303 10 payments
  5. AstraZeneca Pharmaceuticals LP $302 13 payments
  6. Philips Electronics North America Corporation $277 12 payments
  7. Insmed, Inc. $267 19 payments
  8. Mylan Specialty L.P. $236 13 payments
  9. Sunovion Pharmaceuticals Inc. $211 14 payments
  10. Actelion Pharmaceuticals US, Inc. $189 11 payments
  11. Other $1,534 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,390 263 payments
  2. Education $233 5 payments
Products named General payments · program years 2019–2024
  1. TRELEGY ELLIPTA $344 26 payments
  2. OFEV $299 14 payments
  3. Arikayce $267 19 payments
  4. XYREM $212 5 payments
  5. SMARTVEST Hfcwo $206 14 payments
  6. UPTRAVI $189 11 payments
  7. OPSUMIT $189 11 payments
  8. SMARTVEST Hfcwo $189 15 payments
  9. (8874) inCourage $159 7 payments
  10. DUPIXENT $153 6 payments
  11. Other $2,687 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record